How should rituximab be administered, including pre‑chemotherapy medications, chemotherapy regimen, and post‑chemotherapy supportive care?

How to Administer Rituximab: Pre-Chemotherapy, Chemotherapy, and Post-Chemotherapy Medications

Administer rituximab at 375 mg/m² intravenously, with mandatory premedication consisting of acetaminophen and an antihistamine (diphenhydramine or equivalent) given 30-60 minutes before infusion. 1

Pre-Chemotherapy Medications (Premedication)

Standard premedication protocol:

• Acetaminophen (typically 650-1000 mg orally)
• Antihistamine (diphenhydramine 25-50 mg or equivalent H1 antihistamine)
• Timing: Administer 30-60 minutes before rituximab infusion 1

For specific conditions requiring additional premedication:

• Rheumatoid arthritis, GPA/MPA, and pemphigus vulgaris patients: Add methylprednisolone 100 mg IV (or equivalent) 30 minutes prior to each infusion 1
• GPA/MPA induction (adults): Methylprednisolone 1,000 mg IV daily for 1-3 days, followed by oral prednisone 1
• GPA/MPA induction (pediatrics): Methylprednisolone 30 mg/kg IV (max 1 g/day) daily for 3 days before first rituximab infusion 1

Important caveat: When rituximab is given with combination chemotherapy regimens (like R-CHOP), the glucocorticoid component of the chemotherapy regimen should be administered prior to rituximab infusion 1. This is particularly relevant for the 90-minute infusion protocol.

Chemotherapy Administration

Timing Relative to Chemotherapy

Rituximab should be administered 1 day before chemotherapy when used in combination regimens 2. This timing is based on NHL trial protocols and represents the standard approach.

However, there is nuanced evidence regarding sequencing:

• A 2011 study found that patients receiving rituximab after CHOP (CHOP-R sequence) experienced significantly fewer infusion reactions, chills/rigors, higher oxygen saturations, and lower maximum temperatures compared to rituximab before CHOP (R-CHOP sequence) 3
• Despite these tolerability differences, the R-CHOP sequence (rituximab first) remains the established standard based on efficacy data from major trials

Standard Dosing Schedules

For lymphomas and most B-cell malignancies:

• Standard schedule: 375 mg/m² IV weekly for 4 doses 4, 5
• Extended schedule: 375 mg/m² IV weekly for 4 doses, then 4 additional weekly doses at weeks 12-16 for responsive patients 4
• Maintenance (first-line): 375 mg/m² every 8 weeks for 12 doses (high tumor burden patients) 5
• Maintenance (second-line): 375 mg/m² every 12 weeks for 2 years 5

For CD20-positive acute lymphoblastic leukemia:

• Standard: Eight infusions of rituximab at 375 mg/m² over the course of treatment cycles 2
• Administered 1 day before chemotherapy in each cycle

Infusion Rate and Administration

Preparation:

• Dilute rituximab to final concentration of 1-4 mg/mL in 0.9% sodium chloride or 5% dextrose 1
• Use sterile technique; inspect for particulates (should be clear, colorless liquid)
• Do not mix with other drugs 1

Storage of diluted solution:

• Refrigerate at 2-8°C for up to 24 hours (preferred)
• Stable at room temperature for additional 24 hours, but refrigeration recommended 1

Infusion considerations:

• First infusion typically requires slower rates and close monitoring
• Subsequent infusions can be administered more rapidly if first infusion tolerated
• A 30-minute infusion protocol has been shown safe and effective for patients who previously tolerated a 90-minute infusion 6
• Infusion reactions most common during first exposure (30-120 minutes after start) 1

Post-Chemotherapy Medications and Supportive Care

Antimicrobial Prophylaxis

Mandatory prophylaxis for specific conditions:

For CLL patients:

• PCP prophylaxis: During treatment and up to 12 months following completion 1
• Herpes virus prophylaxis: During treatment and up to 12 months following completion 1

For GPA/MPA patients:

• PCP prophylaxis: During treatment and for at least 6 months following last rituximab infusion 1

For pemphigus vulgaris patients:

• PCP prophylaxis: Should be considered during and following rituximab treatment 1

General recommendation:

• Consider prophylaxis for tumor lysis syndrome in appropriate patients 5
• Monitor for viral reactivation (CMV, hepatitis B) 5

Growth Factor Support

Granulocyte colony-stimulating factor (G-CSF):

• Prophylactic G-CSF recommended when rituximab combined with chemotherapy, particularly in older patients 7
• Important for preventing neutropenic complications
• Late-onset neutropenia (LON) can occur with rituximab, especially when combined with chemotherapy 4

Monitoring and Follow-up

Critical monitoring parameters:

IgM flare (Waldenström's macroglobulinemia patients):

• Occurs in ~50% of patients, typically during first months of treatment 4
• Can persist for several months
• Not indicative of treatment failure - do not interpret as progression 4
• High-risk patients (IgM ≥4000 mg/dL): Undergo prophylactic plasmapheresis OR avoid rituximab during first 1-2 courses until IgM decreases 4

Infusion reaction management:

• Monitor vital signs closely during and after infusion
• Watch for hypotension, hypoxia, bronchospasm, angioedema 1
• Have emergency medications readily available
• Most reactions occur during first infusion within 30-120 minutes 1

Infection surveillance:

• Monitor for opportunistic infections throughout treatment and post-treatment period
• Maintain high index of suspicion for PCP, herpes viruses, CMV
• Consider viral surveillance in high-risk patients 8

Hematologic monitoring:

• Regular CBC monitoring for late-onset neutropenia
• Can occur weeks to months after rituximab completion
• Associated with specific FcγRIIIa polymorphisms 4

Common Pitfalls to Avoid

1. Do not skip premedication - acetaminophen and antihistamine are mandatory, not optional 1

2. Do not misinterpret IgM flare as treatment failure in Waldenström's patients - this is an expected phenomenon 4

3. Do not discontinue PCP prophylaxis prematurely - continue for specified duration post-treatment 1

4. Do not administer rituximab to patients with high IgM (≥4000 mg/dL) without plasmapheresis - risk of hyperviscosity complications 4

5. Do not use diluted rituximab solutions beyond stability timeframes - refrigerate and use within 24 hours preferably 1

6. Do not mix rituximab with other drugs in the infusion bag 1

7. Do not assume all patients need corticosteroid premedication - this is condition-specific (RA, GPA/MPA, PV) or when part of chemotherapy regimen 1